Who Optimizes SG&A Costs Better? Sanofi or Viking Therapeutics, Inc.

Sanofi vs. Viking: SG&A Cost Management Showdown

__timestamp	Sanofi	Viking Therapeutics, Inc.
Wednesday, January 1, 2014	8565000000	1244910
Thursday, January 1, 2015	9496000000	5029636
Friday, January 1, 2016	9592000000	4846776
Sunday, January 1, 2017	10164000000	5329003
Monday, January 1, 2018	9934000000	7121000
Tuesday, January 1, 2019	9883000000	9128000
Wednesday, January 1, 2020	9390000000	10731000
Friday, January 1, 2021	9555000000	10701000
Saturday, January 1, 2022	10539000000	16121000
Sunday, January 1, 2023	10765000000	37021000
Monday, January 1, 2024	9183000000

Infusing magic into the data realm

Optimizing SG&A: A Tale of Two Companies

In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Sanofi, a global leader, and Viking Therapeutics, Inc., a burgeoning biotech firm, offer a fascinating study in contrasts. From 2014 to 2023, Sanofi's SG&A expenses have shown a steady increase, peaking at approximately $10.8 billion in 2023. This represents a growth of about 26% over the decade. In contrast, Viking Therapeutics, Inc. started with a modest $1.2 million in 2014, skyrocketing to $37 million by 2023, marking an astonishing 2,875% increase. While Sanofi's expenses reflect its expansive global operations, Viking's surge indicates aggressive growth and investment in its pipeline. This data underscores the different strategies employed by established giants and ambitious newcomers in the pharmaceutical industry.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025